bioMérieux S.A. (BMXXY) Stock
bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About bioMérieux S.A.
bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases. Its operations span the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. The company provides sophisticated diagnostic platforms that analyze biological specimens to pinpoint infectious diseases, cardiovascular conditions, and various cancers. Additionally, it offers microbiological testing for quality control in manufacturing, serving the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele encompasses clinical and hospital laboratories, medical practitioners, blood banks, and industrial control facilities. Founded in 1963, the company, previously known as B-D Mérieux, maintains its headquarters in Marcy l'Etoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
bioMérieux S.A. is headquartered in FR.
bioMérieux S.A. (BMXXY) stock trades at $7.60 with a market capitalization of $8.96B. The stock is valued at a price-to-earnings (P/E) ratio of 21.32, price-to-book of 2.06, price-to-sales of 2.08. Over the past 52 weeks the stock has ranged between $7.12 and $14.62, and currently trades 48.0% below its 52-week high. It pays a dividend yielding 1.45%.
On profitability, bioMérieux S.A. generates a return on equity (ROE) of 9.89%, return on capital employed of 8.61%, an operating margin of 9.54%, a net profit margin of 9.76%.
Official website: www.biomerieux.com